Arthritis, Rheumatoid Clinical Trial
Official title:
A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo Controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis in Patients Who Have Had an Inadequate Response to Methotrexate
Verified date | May 2019 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
Status | Completed |
Enrollment | 379 |
Est. completion date | February 11, 2014 |
Est. primary completion date | February 11, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subject has rheumatoid arthritis (RA) diagnosed according to the 1987 revised ACR criteria for at least 6 months prior to Screening - Subject has been treated with oral methotrexate (MTX) for a minimum of 90 days and at a stable dose for 28 days prior to the first dose of study drug - =6 tender/painful joints; =6 swollen joints - Subject meets the ACR 1991 Revised Criteria for Global Functional Status in RA Class I, II or III at Screening and Baseline - Subject's other medication taken for treatment of RA must be stable for at least 28 days prior to start of the study - Male and female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation - Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration - Subject agrees not to participate in another interventional study while on treatment Exclusion Criteria: - Positive Mycobacterium tuberculosis (TB) test within 90 days of Screening - Abnormal chest x-ray indicative of an acute or chronic infectious process or malignancy - Receipt of live or live attenuated virus vaccination within 30 days prior to the first dose of study drug - Known history of positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody or history of a positive test for human immunodeficiency virus (HIV) infection - History of any other autoimmune rheumatic disease, other than Sjogren's syndrome - Previous history of clinically significant infections or illness (requiring hospitalization or requiring parenteral therapy) within 90 days of the Baseline visit, or a history of any illness that would preclude participation in the study - History of any malignancy, except for successfully treated basal or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix - Does not meet specified washout criteria for the following RA medications: gold, azathioprine, minocycline, penicillamine, etanercept, certolizumab, adalimumab, golimumab, infliximab, cyclophosphamide, and leflunomide - Subject has previously used a non anti-TNF biologic disease-modifying antirheumatic drug (DMARD) (e.g., anakinra, abatacept, rituximab, tocilizumab) - Previous intolerance to Janus kinase (JAK) inhibitors - Receipt of intra-articular or parenteral corticosteroid within 28 days prior to the first dose of study drug or is currently taking > 30 mg oral morphine (or narcotic equivalent) per day - Absolute lymphocyte count (ALC) < 750/mm3 - Receipt of plasma exchange therapy within 60 days prior to the start of study drug - Receipt of any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to first dose of study drug - Receipt of medications that are CYP3A substrates with narrow therapeutic range within 14 days prior to first dose of study drug - History of heart failure, defined as New York Heart Association (NYHA) grade 3 or greater - History of long QT syndrome or prolonged QT interval - Any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, or infectious disease, or any ongoing illness which would make the subject unsuitable for the study. This includes stomatitis, gastrointestinal ulcers, or any other condition that would preclude continued treatment with methotrexate - Subject has any condition possibly affecting oral absorption (e.g., gastrectomy, other malabsorption syndromes, or clinically significant diabetic gastroenteropathy) |
Country | Name | City | State |
---|---|---|---|
Belgium | Hospital Erasme | Brussels | |
Belgium | Moliere Hospital | Brussels | |
Bulgaria | MHAT Burgas | Burgas | |
Bulgaria | MHAT Plovdiv AD | Plovdiv | |
Bulgaria | MHAT "Sv. Ivan Rilski" | Sofia | |
Colombia | Centro Integral de Reumatología del Caribe S.A.S | Barranquilla | |
Colombia | Centro Integral De Reumatologia E Inmunologia | Bogota | |
Colombia | Medicity Sas | Bucaramanga | |
Colombia | Servimed E.U. | Bucaramanga | |
Colombia | Centro de medicina Interna Julian Coronel | Cali | |
Colombia | IPS Rodrigo Botero SAS | Medellin | Antioquia |
Czechia | Revmatologicky ustav | Praha 2 | |
Czechia | MEDICAL PLUS, s.r.o. or REVMACENTRUM UH, s.r.o. | Uherske Hradiste | |
Czechia | PV-MEDICAL s.r.o. | Zlin | |
Hungary | DRC Gyogyszervizsgalo Kozpont Kft | Balatonfured | |
Hungary | Rethy Pal Korhaz es Rendelointezet | Bekescsaba | |
Hungary | Revita Clinic Rheumatology | Budapest | |
Hungary | Kenezy Hospital Institute of Clinical Pharmacology | Debrecen | |
Mexico | Dr Javier Orozco Alcala Private Doctor´s office | Guadalajara | |
Mexico | Hospital Civil de Guadalajara Fray Antonio Alcalde Gutierrez | Guadalajara | |
Mexico | Morales Vargas Centro de Investigacion, SC Rheumatology | Leon | Guanajuato |
Mexico | Cliditer S.A. de C.V.Huerta S.I. | Mexico D.F. | |
Mexico | Centro de Investigacion Clinica de Morelia, S.C. | Morelia | |
Poland | Centrum Osteoporozy i Chorob KKostno-Stawowych Daniluk Clinical Research Centre | Bialystok | |
Poland | NZOZ Osteo-Medic sc A. Racewicz, J. Supronik | Bialystok | |
Poland | Szpital Uniwersytecki nr. 2 im. Dr. Jana Biziela | Bydgoszcz | |
Poland | NZOZ Centrum Medyczne ProMiMed | Krakow | |
Poland | Zespol Poradni Specjalistycznych REUMED sp. Zo.o | Lublin | |
Poland | ARS Rheumatica | Warszawa | |
Poland | Rheuma Medicus Zaktad Opieki Zdrowotnej Relle Brkolozka | Wraszawa | |
United States | Austin Rheumatology Research PA | Austin | Texas |
United States | Achieve Clinical Research, LLC | Birmingham | Alabama |
United States | Center for Arthritis & Rheumatic Disease, P.C. | Chesapeake | Virginia |
United States | Mountain State Clinical Research | Clarksburg | West Virginia |
United States | Arthritis Associates of Colorado Springs | Colorado Springs | Colorado |
United States | Altoona Center for Clinical Research | Duncansville | Pennsylvania |
United States | Center for Arthritis and Osteoporosis | Elizabethtown | Kentucky |
United States | PMG Research | Hickory | North Carolina |
United States | The Talbert Group | Huntington Beach | California |
United States | Rheumatology Consultants, PLLC | Knoxville | Tennessee |
United States | University of California San Diego | La Jolla | California |
United States | Illinois Bone & Joint | Morton Grove | Illinois |
United States | Health Research of Oklahoma | Oklahoma City | Oklahoma |
United States | Arthritis Associates | Orlando | Florida |
United States | Desert Medical Advances | Palm Desert | California |
United States | Pacific Arthritis Center Medical Group | Santa Maria | California |
United States | Deerbrook Medical Asssociates | Vernon Hills | Illinois |
United States | The Center for Rheumatology and Bone Research | Wheaton | Maryland |
United States | Clincal Research Center of Reading | Wyomissing | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Inc |
United States, Belgium, Bulgaria, Colombia, Czechia, Hungary, Mexico, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response | Week 12 | ||
Primary | Trough plasma concentration of ASP015K and metabolite(s) | up to Week 12 | ||
Secondary | Percentage of subjects achieving ACR 50 response | Week 12 | ||
Secondary | Percentage of subjects achieving ACR 70 response | Week 12 | ||
Secondary | Change from baseline in Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) | Baseline and Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 |